WADA - WADA Technical Document – ISL TD2027MRL

WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 1 / 14

MINIMUM REPORTING LEVELS APPLIED IN DOPING CONTROL 1.0 Introduction The objective of this Technical Document (TD), which constitutes an integral part of the International Standard for Laboratories (ISL [1]), is to harmonize the reporting by Laboratories of Adverse Analytical Findings (AAFs) for certain Non-Threshold Substances in urine Samples. For this, Minimum Reporting Levels (MRLs) have been established as a Laboratory reporting requirement. 2.0 Confirmation Procedure Requirements for Non-Threshold Substances Subject to a Minimum Reporting Level The Confirmation Procedure (CP) of Non-Threshold Substances with an MRL shall be based, at a minimum, on the use of the following: a) An adequate internal standard (ISTD). b) A Single-Point Calibrator (SPC) prepared in the matrix of analysis (e.g., urine) at a concentration corresponding to 150% of the MRL. The SPC shall be used to estimate the concentration of the Analyte in the Sample. This estimation shall be based on the comparison of the analytical signal ratio (relative to the ISTD) of the Analyte in the Sample with the corresponding analytical signal ratio of the Analyte in the SPC. c) A Quality Control (QC) sample prepared at a concentration corresponding to the MRL in the same matrix of analysis as the SPC. The QC sample (s) shall be prepared from a different batch or different stock solution of Reference Material (RM) than the SPC.

c) A Quality Control (QC) sample prepared at a concentration corresponding to the MRL in the same matrix of analysis as the SPC. The QC sample (s) shall be prepared from a different batch or different stock solution of Reference Material (RM) than the SPC. [Comment to Article 2.0: Additional QCs and Calibrators can also be used by the Laboratories. For example, the Laboratory may also use an additional Calibrator with a concentration closer to the level estimated in the Sample whenever the Analyte concentration estimated during the ITP is well higher than the MRL (e.g., ≥ 5 x MRL).] d) A CP ensuring that the same analytical condition s applied to estimate the concentration(s) of the Analyte(s) is applied for the identification of the Analyte(s) in accordance with the identification criteria defined in the ISL TD IDCR [2]. The Analyte and ISTD in the Sample, SPC, and QC shall be analyzed under analytical conditions that ensure the reliable identification of the Analyte and the estimation of its concentration in the Sample.WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 2 / 14

3.0 Reporting Requirements for Non-Threshold Substances Subject to an MRL 3.1 Reporting of Findings at Estimated Concentrations higher than (>) the MRL. 3.1.1 “A” Sample To report an AAF for a Non-Threshold Substance subject to an MRL, the Laboratory shall establish with sufficient confidence that the Analyte of the Non-Threshold Substance is present in the “A” Sample at an estimated concentration level exceeding the MRL, in accordance with the following criteria:

To report an AAF for a Non-Threshold Substance subject to an MRL, the Laboratory shall establish with sufficient confidence that the Analyte of the Non-Threshold Substance is present in the “A” Sample at an estimated concentration level exceeding the MRL, in accordance with the following criteria: a) The ISL TD IDCR [2] identification criteria for the Analyte in the Sample are met, and b) The estimated concentration of the Analyte in the Sample, as defined in Table 1, shall be higher than (>) the SPC concentration (i.e., > 150% of the MRL), and the estimated concentration of the Analyte in the QC shall be lower than (<) the SPC concentration (i.e., < 150% of the MRL), and [Comment to Article 3.1.1 b): The Laboratory can confidently conclude that the concentration of the Analyte in the Sample exceeds the MRL only when it exceeds the concentration of the Analyte in the SPC (i.e., > 150% of the MRL), which in turn exceeds the concentration of the Analyte in the QC.] c) When the Specific Gravity (SG) of the urine “A” Sample (SGSample) is higher than (>) 1.018 (as measured by the Laboratory during the CP), and the estimated concentration of the Analyte fulfils the criterion b) above, the concentration shall be adjusted to a SG = 1.020 as per Eq. 1 below. The finding would constitute an AAF only if the adjusted concentration (Concadj) exceeds 150% of the MRL. (Eq. 1) 𝐂𝐨𝐧𝐜𝐚𝐝𝐣 = (𝟏.𝟎𝟐𝟎−𝟏)

150% of the MRL. (Eq. 1) 𝐂𝐨𝐧𝐜𝐚𝐝𝐣 = (𝟏.𝟎𝟐𝟎−𝟏) 𝐒𝐆𝑺𝒂𝒎𝒑𝒍𝒆_𝐌𝐚𝐱 −𝟏 × 𝐂𝐨𝐧𝐜𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝 Where SGSample_Max is calculated as: (Eq. 2) SGSample_Max = SGSample + UMax_SG = SGSample + 0.002 d) If reporting the estimated concentration (adjusted for SGSample, where applicable) of the Analyte in a Sample is necessary (e.g., upon written request by the Testing Authority (TA) or Results Management Authority (RMA), if different, or WADA), the Laboratory shall express the value to the same number of significant figures as the corresponding MRL. 3.1.2 “B” Sample The “B” Sample result for a Non-Threshold Substance subject to an MRL shall only confirm the presence of the Analyte(s) (in compliance with the ISL TD IDCR [2]) in the Sample, at any concentration, for the AAF to be valid.WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 3 / 14

3.2 Reporting of Findings at Estimated Concentrations not higher than (≤) the MRL

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 3 / 14

3.2 Reporting of Findings at Estimated Concentrations not higher than (≤) the MRL There are specific circumstances where the Laboratory may report the presence of a Non-Threshold Substance subjected to an MRL when the Non-Threshold Substance is present in a Sample at an estimated concentration ≤ MRL (adjusted for SGSample, where applicable as per Article 3.1.1.c). 3.2.1 Reporting for Results Management and Target Testing Purposes a) The Laboratory shall report findings at an estimated concentration ≤ MRL as Atypical Findings (ATFs) as established in the relevant ISL TDs [3-4] or ISL TLs [5-7]. b) For avoidance of doubt, as established in the ISL [1], nothing shall prevent the Laboratory, upon written request by the TA or RMA (if different) or WADA, from disclosing to the requesting Anti-Doping Organization (ADO) information about the presence of a Non-Threshold Substance with an MRL at an estimated concentration ≤ MRL. A justification to do so, as provided by the ADO (e.g., if the analysis is part of a Results Management process, an ongoing investigation, or Target Testing of the Athlete), shall be kept as part of the Sample records. 3.2.2 Reporting an Atypical Finding in the Co-Presence of a Diuretic or Masking Agent The Laboratory shall report the finding for a Non-Threshold Substance subject to MRL at an estimated concentration ≤ MRL as an ATF when the Analyte is identified (in compliance with the ISL TD IDCR [2]) in the co-presence of a diuretic or masking agent in the Sample. If the diuretic or masking agent is subject to an MRL, its estimated concentration shall be higher than (>) the relevant MRL, as established in accordance with Article 3.1.

ISL TD IDCR [2]) in the co-presence of a diuretic or masking agent in the Sample. If the diuretic or masking agent is subject to an MRL, its estimated concentration shall be higher than (>) the relevant MRL, as established in accordance with Article 3.1. [Comment to Article 3.2.2: As per the ISL Article 5.3.4.1.3 [1], when there is a Presumptive Adverse Analytical Finding (PAAF) for a diuretic, the Laboratory may contact the TA (or RMA, if different) to enquire whether an approved Therapeutic Use Exemption exists for the diuretic. However, where a diuretic is detected in a Sample together with a Non-Threshold Substance subject to MRL, the Laboratory shall proceed with the CP of both substances and report the confirmed findings according to this ISL TD MRL. Whether there is an approved Therapeutic Use Exemption for the diuretic and/or the Non-Threshold Substance shall be determined during the Results Management process.]WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 4 / 14

4.0 List of Minimum Reporting Levels per Class of Prohibited Substances Table 1 specifies the Non-Threshold Substances that are subject to MRL, according to the corresponding Prohibited Substance class (as defined in the Prohibited List [8]), and the applicable MRL (in ng/mL). Table 1 also includes a Comments column providing guidance and references for the correct application of the MRLs. Wherever the target Analyte(s) specified in this column are defined as the total content of the free

Table 1 also includes a Comments column providing guidance and references for the correct application of the MRLs. Wherever the target Analyte(s) specified in this column are defined as the total content of the free (non-conjugated) substance and its respective phase-II glucuroand/or sulfconjugated Metabolites expressed as free compound equivalent, the determination can be performed by the Laboratory either after deconjugation (where the total content is obtained from the sum of the free fraction plus tha t released from the phase -II glucuronidated/sulfated fraction after hydrolysis ) or through the direct detection of the free compound and the conjugated phase-II Metabolite(s). [Comment to Article 4.0 : When the target Analyte is referred to as “free (non-conjugated) parent compound form”, this means that Laboratories shall target only the unmodified form of the substance, without considering any phase-I or phase-II Metabolites]. Table 1. MRLs applicable to urine Samples per Class of Prohibited Substances or Prohibited Method Prohibited Class MRL (ng/mL) Comments S1.1 Anabolic Androgenic Steroids (AAS) The MRL applies only to the following AAS: 6-hydroxy-androstenedione (6-OH-AD), 19-norandrosterone (19-NA), and boldenone and its Metabolite (5β-androst-1-en-17β-ol-3-one).

6-OH-AD 10

This MRL is applied to the total content of 6-OH-AD, including the free, non-conjugated 6-OHAD and its phase-II glucuroconjugated form, expressed as 6-OH-AD equivalent. Samples with 6-OH-AD concentrations above the MRL and no signs of extensive Sample degradation shall be subjected to GC/C/IRMS analysis.

AD and its phase-II glucuroconjugated form, expressed as 6-OH-AD equivalent. Samples with 6-OH-AD concentrations above the MRL and no signs of extensive Sample degradation shall be subjected to GC/C/IRMS analysis. Refer to the ISL TD MRPL [9], ISL TD IRMS [3] and ISL TL21 [10]. 19-NA 15 This MRL is applied to the total content of 19-NA, including the free, non-conjugated 19-NA and its phase-II glucuroconjugated form, expressed as 19-NA equivalent. Analytical findings with 19-NA concentrations above the MRL shall be reported as AAF without the need to conduct GC/C/IRMS analysis (except for females who are pregnant or using norethisterone) [4]. Refer to the ISL TD MRPL [9] and ISL TD NA [4]. Boldenone / Boldenone Metabolite (5β-androst-1-en17β-ol-3-one) 30

1. This MRL is applied to the total content of boldenone or to the total content of the boldenone Metabolite, including the free, non -conjugated boldenone or boldenone Metabolite and their respective phase -II glucuroconjugated form s, expressed as boldenone or boldenone Metabolite equivalent, respectively. Analytical findings with boldenone or boldenone Metabolite concentrations above the MRL shall be reported as AAF without the need to conduct C/C/IRMS analysis. ii. The MRL shall not be applied to the sum of estimated total concentrations of boldenone and boldenone Metabolite.

Refer to the ISL TD MRPL [9] and ISL TD IRMS [3].WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

boldenone Metabolite. Refer to the ISL TD MRPL [9] and ISL TD IRMS [3].WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 5 / 14

Prohibited Class MRL (ng/mL) Comments S1.2 Other Anabolic Agents The MRL applies only to the following Other Anabolic Agents: clenbuterol, ractopamine, zeranol, and zilpaterol - refer to ISL TL23 [5] Clenbuterol 5 The MRL is applied to the free (non-conjugated) clenbuterol. Ractopamine The MRL is applied to the total content of ractopamine, including the free (non -conjugated) ractopamine and its respective phase-II glucuroand sulfoconjugated Metabolites expressed as ractopamine equivalent.

Zeranol The MRL is applied to: − The total content of zeranol, including the free (non-conjugated) zeranol and its respective phase-II glucuroconjugated Metabolite expressed as zeranol equivalent; and/or − The total content of the zeranol phase -I Metabolite taleranol, including the free

(unconjugated) taleran ol and its respective phase -II glucuroconjugate d Metabolite, expressed as taleranol equivalent. However, the MRL is independently applied to each target Analyte (i.e., total content of either zeranol or taleranol) and shall not be applied to the sum of the estimated concentrations of these different molecular species.

expressed as taleranol equivalent. However, the MRL is independently applied to each target Analyte (i.e., total content of either zeranol or taleranol) and shall not be applied to the sum of the estimated concentrations of these different molecular species. For zeranol findings related to possible mycotoxin origin, refer to ISL TL04 [11]. Zilpaterol The MRL is applied to the free (non-conjugated) zilpaterol. S3. Beta-2 Agonists The MRL applies only to the following beta-2 agonists: higenamine, vilanterol, salmeterol and tretoquinol. Higenamine 10 The MRL is applied to the free (non-conjugated) parent compound form. Vilanterol Salmeterol Tretoquinol 20 The MRL is applied to the total content of tetroquinol, including the free (non -conjugated) tetroquinol and its respective phase -II glucuroconjugated Metabolite, expressed as tetroquinol equivalent. [Comment to S3. Beta-2 Agonists: Tretoquinol is used therapeutically for the treatment of asthma and is also used as an ingredient of over-the-counter (OTC) cold and flu medications. Therefore, an MRL is established to avoid the reporting of an AAF for tretoquinol, which may have resulted from the inadvertent use of tretoquinol-containing OTC medications [12,13]] S4.1 Aromatase Inhibitors The MRL applies only to the following Aromatase Inhibitor: formestane. Formestane 150 This MRL is applied to the total content of formestane, including the free , non-conjugated formestane and its respective phase -II glucuroconjugated form, expressed as formestane equivalent). Analytical findings with formestane concentrations above the MRL shall be reported

This MRL is applied to the total content of formestane, including the free , non-conjugated formestane and its respective phase -II glucuroconjugated form, expressed as formestane equivalent). Analytical findings with formestane concentrations above the MRL shall be reported as AAF without the need to conduct GC/C/IRMS analysis. Refer to the ISL TD MRPL [14] and ISL TD IRMS [3].WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 6 / 14

Prohibited Class MRL (ng/mL) Comments S4.2 Anti-Estrogenic Substances The MRL applies only to the following anti-estrogenic substance: clomifene. Clomifene 2 The MRL is applied to the free (non-conjugated) clomifene (as the sum of both isomers: zuclomifene and enclomifene). See also ISL TL26 [7] S4.4 Metabolic Modulators The MRL applies only to the following Metabolic Modulator: Meldonium. Meldonium 100 The MRL is applied to the free (non-conjugated) meldonium. S5. Diuretics and Masking Agents Diuretics The MRL applies only to the following diuretics: acetazolamide, bumetanide, furosemide, hydrochlorothiazide, chlorothiazide (in the presence of hydrochlorothiazide), torasemide, and triamterene. Refer to ISL TL24 [6] Acetazolamide 20

the presence of hydrochlorothiazide), torasemide, and triamterene. Refer to ISL TL24 [6] Acetazolamide 20 The MRL is applied to the free (non-conjugated) parent compound [6].

Bumetanide Furosemide Torasemide Triamterene Hydrochlorothiazide Chlorothiazide (in the presence of hydrochlorothiazide) The MRL is applied to the free (non -conjugated) chlorothiazide (which may form from hydrochlorothiazide) only when chlorothiazide is detected in a Sample in the co -presence of hydrochlorothiazide at less than (<) 20 ng/mL Masking Agents The MRL applies only to the following masking agents: dextran, mannitol, and probenecid. Dextran 5,000,000 (5 mg/mL) The MRL is applied to the free (non-conjugated) parent compound. Mannitol Probenecid 200WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 7 / 14

Prohibited Class MRL (ng/mL) Comments S6. Stimulants Unless specified below, the MRL of 50 ng/mL applies for all stimulants to the total content of substance, including the free (nonconjugated) parent compound and its respective phase -II glucuroconjugated Metabolite, expressed as parent compound

S6. Stimulants Unless specified below, the MRL of 50 ng/mL applies for all stimulants to the total content of substance, including the free (nonconjugated) parent compound and its respective phase -II glucuroconjugated Metabolite, expressed as parent compound equivalent. The MRL shall not be applied to phase-I Metabolite(s). Stimulants with MRL applied to the Free (non-conjugated) Parent Compound only 4-methylhexan-2-amine 50

5-methylhexan-2-amine Amfetamine Etilefrine Famprofazone Fladrafinil Flmodafinil Fonturacetam (carphedon) Heptaminol MDMA (Methylenedioxymethamphetamine) MDA (Methylenedioxyamphetamine) Mephedrone Nikethamide Norfenefrine Pemoline Phenmetrazine Strychnine Tuaminoheptane Stimulants with MRL applied to specific Metabolites and/or with Specific Requirements Adrafinil Modafinil 50 The MRL is applied to the free (non-conjugated) modafinil acid (the main Metabolite of Adrafinil and Modafinil). Bromantan The MRL is applied to the total content of bromantan phase-I Metabolite (6-hydroxy-bromantan), including the free (non -conjugated) 6-hydroxy-bromantan and its respective phase -II glucuroconjugated form, expressed as 6-hydroxy-bromantan equivalent.WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee

Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 8 / 14

Prohibited Class MRL (ng/mL) Comments Stimulants with MRL applied to specific Metabolites and/or with Specific Requirements (cont.) Cocaine (parent compound) 10

1. The MRL is applied to the free (non -conjugated) cocaine or its free (non -conjugated) major Metabolite benzoylecgonine. ii. The MRL is independently applied to each target Analyte and shall not be applied to the sum of estimated concentrations of different molecular species. iii. The Laboratory shall report the estimated concentration of the relevant target Analyte(s) (i.e., cocaine and/or benzoylecgonine), which led to the AAF (i.e., present in the Sample at levels higher than (>) the corresponding MRL). iv. In addition, for Results Management purposes, where benzoylecgonine is present in a Sample at levels higher than (>) its MRL of 50 ng/mL (and reported as an AAF), but cocaine is absent or present at levels lower than or equal to (≤) 10 ng/mL, the Laboratory shall also confirm the presence (or absence) of cocaine in the Sample and provide the estimated concentration of cocaine (if between 1-10 ng/mL) in the Test Report.

Benzoylecgonine (major Metabolite of cocaine) 50 Clobenzorex 50 The MRL is applied to the total content of clobenzorex phase -I Metabolite (4-hydroxyBenzoylecgonine (major Metabolite of cocaine) 50 Clobenzorex 50 The MRL is applied to the total content of clobenzorex phase -I Metabolite (4-hydroxyclobenzorex), including the free (non -conjugated) 4-hydroxy-clobenzorex and its respective phase-II glucuroconjugated form, expressed as 4-hydroxy-clobenzorex equivalent. Dobutamine The MRL is applied to the total content of dobutamine, including the free (non -conjugated) dobutamine and its respective phase-II glucuronidated and sulfated Metabolites, expressed as dobutamine equivalent. Hydroxyamfetamine (parahydroxyamphetamine, p-OH-A)

1. The MRL is applied to the total content of p-OH-A, including the free (non-conjugated) p-OH-A and its respective phase-II glucuronidated Metabolite, expressed as p-OH-A equivalent. ii. Before reporting an AAF based only on the detection of p-OH-A, the Laboratory shall confirm the absence of mebeverine-specific Metabolites: mebeverine acid and desmethyl mebeverine acid to exclude mebeverine as the primary source of p-OH-A [15-18].

[Comment to Hydroxyamfetamine : Mebeverine is a non -prohibited antispasmodic substance used for the treatment of irritable bowel disease, which can metabolize into p -OH-A. The mebeverine parent compound is not detected in urine, and its acidic Metabolites: veratric acid, vanillic acid, isovanillic acid, and protocatechuic acid are not specific because they can originate from the ingestion of certain foods) [15].] Meclofenoxate 50 The MRL is applied to the free (non-conjugated) meclofenoxate. Refer to ISL TL01 [19].

protocatechuic acid are not specific because they can originate from the ingestion of certain foods) [15].] Meclofenoxate 50 The MRL is applied to the free (non-conjugated) meclofenoxate. Refer to ISL TL01 [19]. 4-Chlorophenoxyacetic acid (4-CPA) 5,000 (5 µg/mL) The MRL is applied to the free (non-conjugated) 4-CPA – Refer to ISL TL01 [3] Mephentermine

Phentermine 50

1. The MRL is applied to the free (non-conjugated) parent compound. ii. The MRL is independently applied to each target Analyte and shall not be applied to the sum of estimated concentrations of different molecular species. iii. Before reporting an AAF based on the detection of mephentermine or phentermine, the Laboratory shall confirm that oxethazaine-specific Metabolites: β-hydroxyphentermine and β- hydroxymephentermine are in lower concentration than mephentermine and/or phentermine to exclude oxethazaine as the primary source of the findings. [20].

[Comment to Mephentermine / Phentermine : Oxethazaine is a non -prohibited topical anaesthetic prescribed for the treatment of acute and chronic gastritis and duodenitis, which can metabolize into mephentermine and phentermine. Following the administration of oxethazaine, its major Metabolites β - hydroxyphentermine and β -hydroxymephentermine are detected in much higher concentrations than mephentermine and/or phentermine [20].]WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 9 / 14

Prohibited Class MRL (ng/mL) Comments Stimulants with MRL applied to specific Metabolites and/or with Specific Requirements (cont.) Mesocarb 50 The MRL is applied to the total content of mesocarb phase -I Metabolite (p-hydroxy-mesocarb) and its respective phase -II glucuroconjugated form, expressed as p-hydroxy-mesocarb equivalent Metamfetamine Levmetamfetamine (dand l-metamfetamine)

1. The MRL is applied to the free (non-conjugated) metamfetamine or to the free (non-conjugated) levmetamfetamine. ii. The two optical isomers of metamfetamine [namely dand l-metamfetamine] are classified under different categories of the Prohibited List. Metamfetamine ( d-) is classified as a nonspecified stimulant (S6.A), whereas levmetamfetamine ( l-) is a specified stimulant (S6.B).

Since this differential classification may lead to different periods of Ineligibility, the MRL is applied independently to these two enantiomers, which means that the Laboratory shall be able to separate them chromatographically. Methylphenidate Ethylphenidate The MRL is applied to the free (non -conjugated) ritalinic acid (the main Metabolite of methylphenidate and ethylphenidate). Octopamine 1,000

able to separate them chromatographically. Methylphenidate Ethylphenidate The MRL is applied to the free (non -conjugated) ritalinic acid (the main Metabolite of methylphenidate and ethylphenidate). Octopamine 1,000 (1 µg/mL) The MRL is applied to the total content of octopamine, including the free (non -conjugated) octopamine and its respective phase -II sulfated Metabolite, expressed as octopamine equivalent. Oxilofrine (methylsynephrine)

(in the absence of ephedrine)

50 The MRL is applied to the free (non-conjugated) oxilofrine [21, 22]. [Comment to Oxilofrine: Laboratories shall implement procedures that allow the proper chromatographic separation and identification of oxilofrine and hydroxy-pseudoephedrine prior to reporting an AAF for oxilofrine.] (in the presence of ephedrine) 1,000 (1 µg/mL) Prenylamine 50 MRL is applied to the total content of prenylamine phase -I Metabolite (p-hydroxy-prenylamine) and its respective phase -II glucuroconjugated form, expressed as p-hydroxy-prenylamine equivalent. Selegiline

1. The MRL is applied to the total content of selegiline phase -I Metabolite (N-desmethylselegiline) and its respective phase -II glucuroconjugated form, expressed as N -desmethylselegiline equivalent. ii. In addition, metamfetamine and amfetamine may also be present in a Sample as Metabolites of selegiline. The MRL also applies to these free (non-conjugated) phase-I Metabolites. iii. However, the MRL is independently applied to each target Analyte and shall not be applied to

of selegiline. The MRL also applies to these free (non-conjugated) phase-I Metabolites. iii. However, the MRL is independently applied to each target Analyte and shall not be applied to the sum of the estimated concentrations of these different molecular species. Sibutramine

1. The MRL is applied to the total content of any sibutramine phase -I Metabolite [(N,N)- Didemethyl-sibutramine and (N,N) -Didemethyl-1-hydroxy-sibutramine] and their respective phase-II glucuroconjugated forms, expressed as phase-I Metabolite equivalent. ii. However, the MRL is independently applied to each target Analyte and shall not be applied to the sum of the estimated concentrations of these different molecular species.WADA Technical Document – ISL TD2027MRL Document number: ISL TD2027MRL Version number: 1.0

Written by: Reviewed by:

WADA Science / MRPL Working Group WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 17 March 2026 Effective date: 01 January 2027

ISL TD2027MRL - Version 1.0 – 01 January 2027 Page 10 / 14

Prohibited Class MRL (ng/mL) Comments S7. Narcotics Buprenorphine 2.5

1. The MRL is applied to the total content of buprenorphine, including the free (non-conjugated) buprenorphine and its respective phase -II glucuroconjugated form, expressed as buprenorphine equivalent.
2. The MRL is applied to the total content of the Metabolite norbuprenorphine, including the free

(non-conjugated) norbuprenorphine and its respective phase -II glucuroconjugated form, expressed as norbuprenorphine equivalent.

1. The MRL is applied to the total content of the Metabolite norbuprenorphine, including the free

(non-conjugated) norbuprenorphine and its respective phase -II glucuroconjugated form, expressed as norbuprenorphine equivalent. ii. The MRL shall not be applied to the sum of estimated total concentrations of buprenorphine and norbuprenorphine. Diamorphine (heroin) 25 The MRL is applied to the total content of the Metabolite